Dihydrexidine

Dihydrexidine (LS-186,899) is a selective full agonist at the dopamine D1 and D5 receptors. It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor. Dihydrexidine was investigated for the treatment of Parkinson's disease and schizophrenia but in an early clinical trial the drug was given intravenously and led to profound hypotension so development was halted. This drug continues to be studied, however, and is now in clinical trials to assess its efficacy in improving the cognitive and working memory deficits in schizophrenia.